Company intelligence

GRCE

Grace Therapeutics, Inc. · NASDAQ · Healthcare

Price$2.15-2.27% · −$0.05

Market cap34.99MEquity value

P / E-1.8Trailing ratio

Volume21.2KLatest session

Market data

GRCE price chart

TradingView

Related signals

1 min delayed

Browse public GRCE signals with their source context and measured market impact. Open any signal for its permanent analysis page.

GRCEApr 23, 2026-46.39% since signal

Grace Therapeutics Faces FDA Setback but Plans to Resubmit GTx-104 NDA

Grace Therapeutics received a Complete Response Letter from the FDA regarding its GTx-104 application for treating aSAH, citing concerns about chemistry, manufacturing, and non-clinical data. The company is confident that they can address these issues, which could lead to a pivotal approval, marking a significant advancement in aSAH treatment after decades.

View signal analysis

GRCEFeb 10, 2025+0.44% since signal

Small-Cap Grace Therapeutics Touts Positive Data From Brain Hemorrhage Study

GTx-104 trial met primary endpoint, showing clinical benefit over nimodipine. GTx-104 reduced hypotension incidents by 19% in hospitalized aSAH patients. 54% dose intensity for GTx-104 patients was significantly higher than for nimodipine. Grace Therapeutics plans $30 million private placement to fund GTx-104 development. Current GRCE stock price is $3.38, reflecting positive investor sentiment.

View signal analysis

Research